Literature DB >> 36156911

Clinical Outcomes in Breast Cancer Patients with HER2-Positive, Node-Negative Tumors (≤3 cm).

Naoko Iwamoto1, Tomoyuki Aruga1, Shinichiro Horiguchi2.   

Abstract

Entities:  

Keywords:  Adjuvant therapy; Small tumor; Trastuzumab

Year:  2022        PMID： 36156911      PMCID： PMC9453665          DOI： 10.1159/000522198

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN： 1661-3791            Impact factor:   2.268


× No keyword cloud information.
  20 in total

1.  Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial.

Authors:  Matteo Lambertini; Christine Campbell; Richard D Gelber; Giuseppe Viale; Ann McCullough; Florentine Hilbers; Larissa A Korde; Olena Werner; Saranya Chumsri; Christian Jackisch; Antonio C Wolff; Ines Vaz-Luis; Arlindo R Ferreira; Aleix Prat; Alvaro Moreno-Aspitia; Martine Piccart; Sherene Loi; Evandro de Azambuja
Journal:  Breast Cancer Res Treat       Date:  2019-05-27       Impact factor: 4.872

2.  Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.

Authors:  Sara M Tolaney; Hao Guo; Sonia Pernas; William T Barry; Deborah A Dillon; Lauren Ritterhouse; Bryan P Schneider; Fei Shen; Kit Fuhrman; Michele Baltay; Chau T Dang; Denise A Yardley; Beverly Moy; P Kelly Marcom; Kathy S Albain; Hope S Rugo; Mathew J Ellis; Iuliana Shapira; Antonio C Wolff; Lisa A Carey; Beth Overmoyer; Ann H Partridge; Clifford A Hudis; Ian E Krop; Harold J Burstein; Eric P Winer
Journal:  J Clin Oncol       Date:  2019-04-02       Impact factor: 44.544

3.  Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.

Authors:  Sara M Tolaney; William T Barry; Chau T Dang; Denise A Yardley; Beverly Moy; P Kelly Marcom; Kathy S Albain; Hope S Rugo; Matthew Ellis; Iuliana Shapira; Antonio C Wolff; Lisa A Carey; Beth A Overmoyer; Ann H Partridge; Hao Guo; Clifford A Hudis; Ian E Krop; Harold J Burstein; Eric P Winer
Journal:  N Engl J Med       Date:  2015-01-08       Impact factor: 91.245

4.  Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.

Authors:  Edith A Perez; Edward H Romond; Vera J Suman; Jong-Hyeon Jeong; George Sledge; Charles E Geyer; Silvana Martino; Priya Rastogi; Julie Gralow; Sandra M Swain; Eric P Winer; Gerardo Colon-Otero; Nancy E Davidson; Eleftherios Mamounas; Jo Anne Zujewski; Norman Wolmark
Journal:  J Clin Oncol       Date:  2014-10-20       Impact factor: 44.544

5.  High recurrence risk and use of adjuvant trastuzumab in patients with small, HER2-positive, node-negative breast cancers.

Authors:  Akiyo Horio; Takashi Fujita; Hironori Hayashi; Masaya Hattori; Naoto Kondou; Mai Yamada; Eri Adachi; Aya Ushio; Naomi Gondou; Aiko Sueta; Yasushi Yatabe; Hiroji Iwata
Journal:  Int J Clin Oncol       Date:  2011-06-18       Impact factor: 3.402

6.  Regional Nodal Irradiation After Breast Conserving Surgery for Early HER2-Positive Breast Cancer: Results of a Subanalysis From the ALTTO Trial.

Authors:  Isabelle Gingras; Eileen Holmes; Evandro De Azambuja; David H A Nguyen; Miguel Izquierdo; Jo Anne Zujewski; Moshe Inbar; Bjorn Naume; Gianluca Tomasello; Julie R Gralow; Antonio C Wolff; Lyndsay Harris; Michael Gnant; Alvaro Moreno-Aspitia; Martine J Piccart; Hatem A Azim
Journal:  J Natl Cancer Inst       Date:  2017-08-01       Impact factor: 13.506

7.  Distant invasive breast cancer recurrence risk in human epidermal growth factor receptor 2-positive T1a and T1b node-negative localized breast cancer diagnosed from 2000 to 2006: a cohort from an integrated health care delivery system.

Authors:  Louis Fehrenbacher; Angela M Capra; Charles P Quesenberry; Regan Fulton; Parveen Shiraz; Laurel A Habel
Journal:  J Clin Oncol       Date:  2014-06-02       Impact factor: 44.544

8.  Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.

Authors:  Antonio C Wolff; M Elizabeth Hale Hammond; Kimberly H Allison; Brittany E Harvey; Pamela B Mangu; John M S Bartlett; Michael Bilous; Ian O Ellis; Patrick Fitzgibbons; Wedad Hanna; Robert B Jenkins; Michael F Press; Patricia A Spears; Gail H Vance; Giuseppe Viale; Lisa M McShane; Mitchell Dowsett
Journal:  J Clin Oncol       Date:  2018-05-30       Impact factor: 44.544

9.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.

Authors:  Antonio C Wolff; M Elizabeth H Hammond; David G Hicks; Mitch Dowsett; Lisa M McShane; Kimberly H Allison; Donald C Allred; John M S Bartlett; Michael Bilous; Patrick Fitzgibbons; Wedad Hanna; Robert B Jenkins; Pamela B Mangu; Soonmyung Paik; Edith A Perez; Michael F Press; Patricia A Spears; Gail H Vance; Giuseppe Viale; Daniel F Hayes
Journal:  J Clin Oncol       Date:  2013-10-07       Impact factor: 44.544

10.  Treatment patterns and survival in HER2-positive early breast cancer: a whole-of-population Australian cohort study (2007-2016).

Authors:  Monica Tang; Andrea Schaffer; Belinda E Kiely; Benjamin Daniels; Robert J Simes; Chee K Lee; Sallie-Anne Pearson
Journal:  Br J Cancer       Date:  2019-11-01       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.